The last of the triumvirate is romosozumab, the drug for post-menopausal osteoporosis being co-developed with Amgen ... now sell alongside its own neurology products, plus a number of future ...

Mr. Karnani has more than 15 years of leadership experience in the life sciences industry. Over the course of nearly a decade at Horizon Therapeutics, Mr. Karnani held leadership positions spanning ...

Michelle Petri, MD, MPH “In some fields, such as neurology, TDM is accepted for ... of immunogenicity between biosimilars and reference products, it did note discrepancies in how the agents ...

His leadership was instrumental during Horizon's integration into Amgen (NASDAQ ... commercializing products for serious medical conditions. The company's expansion into neurology and its ...

His leadership was instrumental during Horizon's integration into Amgen (NASDAQ ... focuses on developing and commercializing products for serious medical conditions. The company's expansion into ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

AstraZeneca’s AZN third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus ...

neurology, and other applications. In 2022, the musculoskeletal disorders segment accounted for the largest market share.

The merger solves problems for both companies – allowing AbbVie to diversify its portfolio of products ... approved neurology medicines. This leaves Gilead, Pfizer, and Amgen as the likely ...

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat ... The company provides specialty care, such as ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...